Publications
Progress report on new epilepsy treatments: a summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development
Bialer M, Johannessen Landmark C, Koepp MJ, Perucca E, Perucca P, Tomson T, White HS, Wirrell E.
Epilepsia. 2026. doi:10.1002/epi.70354
Includes discussion of SN-2000 and selective PDE4B inhibition.
SN-2000, a Selective Allosteric PDE4B Inhibitor, Demonstrates Broad-Spectrum Antiseizure Activity with Pro-Cognitive and Anxiolytic Properties in Preclinical Epilepsy Models
Kinch CD, Kesler M, Rho J, Teskey GC, McGirr A, Hagen TJ, Kurrasch DM.
EILAT XVIII – Madrid, Spain | May 2026
View Abstract / Meeting Information
Allosteric inhibition of phosphodiesterase 4B as a broad-spectrum therapeutic strategy for refractory epilepsy
Kinch CD, Kesler M, Dogra D, Morin K, Ibhazehiebo K, Rho J, Kurrasch DM.
American Epilepsy Society Annual Meeting – Atlanta, Georgia | December 2025
Allosteric Inhibition of Phosphodiesterase 4B as a Broad-Spectrum Therapeutic Strategy for Refractory Epilepsy
Kinch CD, Kesler M, Dogra D, Morin K, Rho J, Kurrasch DM.
Canadian League Against Epilepsy Annual Scientific Meeting – Calgary, Alberta | October 2025
EILAT XVIII – Madrid, Spain | 2026
SN-2000
Deborah M. Kurrasch, PhD, Stream Neuroscience Inc.
New Therapeutic Agents in Development session.
Epilepsy Foundation Pipeline Conference – Leesburg, Virginia | 2026
Allosteric Inhibition of Phosphodiesterase 4B for Treatment of Refractory Epilepsy
Deborah M. Kurrasch, PhD, Stream Neuroscience
Preclinical Pipeline Speaker Panel.
Epilepsy Therapies & Diagnostics Development XVIII – Leesburg, Virginia | 2025
Allosteric Phosphodiesterase 4B Inhibition as a Novel Strategy for the Treatment of Refractory Epilepsy
Deborah M. Kurrasch, PhD, Stream Neuroscience Inc.
Preclinical Pipeline session.
Epilepsy Foundation Pipeline Conference – Atlanta, Georgia | 2024
Allosteric Phosphodiesterase 4B Inhibition as a Novel Strategy for the Treatment of Refractory Epilepsy
Deborah M. Kurrasch, PhD, Stream Neuroscience Inc.
Preclinical session.
Deborah M. Kurrasch named a 2026 Killam Annual Professor
University of Calgary | 2026
Recognized in part for entrepreneurial work.
No official recipient-specific link found; leave unlinked for now.
Deborah M. Kurrasch awarded a UCalgary Research Excellence Chair
University of Calgary | 2026-2031
Recognition for research excellence and related entrepreneurial impact.
No official recipient-specific link found; leave unlinked for now.
Public outreach in epilepsy and brain health
Calgary, Alberta | 2026
Include Owerko Centre Community Connections and All Aboard the Brain Train at Calgary Central Library.
Owerko Centre Community Connections
Stream Neuroscience presents at the Alberta Innovator Speed Pitch
UCalgary Health & Life Sciences Industry Collaboration Initiative – Calgary, Alberta | September 22, 2026
A New Approach for Focal Epilepsy
Mitchell Kesler, MSc, Director, R&D, Stream Neuroscience
Inhibition of phosphodiesterase 4B as a novel therapeutic strategy for the treatment of refractory epilepsy.
Kinch CD, Kesler M, Dogra DD, Morin K, Ibhazehiebo K, Noschang CG, Rho JM, Kurrasch DM — 17 May 2025 (preprint)
Selective allosteric inhibition of phosphodiesterase 4B (PDE4B) as a potential anti-seizure treatment for Dravet Syndrome
Kinch, CD, et al., American Epilepsy Society 2024 Dec
A concise synthesis of biaryl PDE4D allosteric modulators
Dalby, A, et al.,Tetrahedron Lett. 2013
LINK IS NO LONGER AVAILABLE
kcna1a Mutant Zebrafish model episodic Ataxia type 1 (EA1) with epilepsy and show response to first-line therapy carbamazepine
Dogra, D., Epilepsia 2018 Mar
Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo, K, et al., 2020 May
Metabolism-based drug discovery in zebrafish: an emerging strategy to uncover new anti-seizure therapies.
Ibhazehiebo K, Rho JM, Kurrasch DM — 2020
Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders.
Gurney, ME, et al. J Med Chem. 2019 May
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target.
Ibhazehiebo K, Gavrilovici C, de la Hoz CL, Ma SC, Rehak R, Kaushik G, Meza Santoscoy PL, Scott L, Nath N, Kim DY, Rho JM, Kurrasch DM — 24 January 2018
A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target
Ibhazehiebo, K, et al., Brain, 2018 Mar
Discovery of triazines as selective PDE4B versus PDE4D inhibitors
Dogra, D., Epilepsia 2018 Mar
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
Burgin, AB, et al., Nat Biotechnol. 2010 Jan